Hepatitis B Virus Vaccine Inactivated
drugOn this page
Summary
Hepatitis B Virus Vaccine Inactivated (CHEMBL2109163) is a phase-3 clinical-stage vaccine component; indicated across 6 conditions including chronic kidney disease and hepatitis b virus infection.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- Indications: 6 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109163 |
| Name | Hepatitis B Virus Vaccine Inactivated |
| Type | Vaccine component |
| Max phase | 3 |
Also known as: Hepatitis b virus vaccine inactivated, HEPATITIS B VIRUS VACCINE INACTIVATED
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0003884 |
| hepatitis B virus infection | 3 | MONDO:0005344 | EFO:0004197 |
| streptococcal infection | 3 | MONDO:0021680 | EFO:1001476 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| malaria | 2 | MONDO:0005136 | EFO:0001068 |
| human papilloma virus infection | 2 | MONDO:0005161 | EFO:0001668 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).